CRBU Stock Overview
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally.
Caribou Biosciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$8.55|
|52 Week High||US$32.65|
|52 Week Low||US$4.89|
|1 Month Change||30.73%|
|3 Month Change||16.64%|
|1 Year Change||-61.81%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-47.61%|
Recent News & Updates
Caribou Biosciences: Potential To Change CAR-T Landscape
Proof of concept established using CRISPR allogeneic CAR-T CB-010 for the treatment of patients with relapsed/refractory B-cell Lymphoma. Additional results from the phase 1 ANTLER study using CB-010 for the treatment of patients with relapsed/refractory B-cell Lymphoma are expected by the end of 2022. An IND application for the use of CB-011 for the treatment of patients with relapsed/refractory multiple myeloma is expected in the 2nd half of 2022. Caribou had $390.8 million in cash as of March 31, 2022; enough cash to fund its operations for at least the next 12 months. Caribou Biosciences, Inc. (CRBU) is a great speculative biotech play to look into. The reason why I state that is because it is developing a CRISPR-edited allogeneic CAR-T known as CB-010, which could possibly change the potential treatment landscape for CAR-T. I will go into more detail below, but the gist of the approach is to generate longer persistence compared to other CAR-Ts out there. It is advancing CB-010 in a phase 1 study treating patients with relapsed/refractory B-cell non-Hodgkin Lymphoma ((NHL)). Not only that, but there is a possibility that it could possibly advance this study quickly by having the potential to turn a phase 2 study into a registrational one. It is also advancing other candidates for hematology in that it is developing CB-011 as an allogenic CAR-T targeting BCMA for relapsed/refractory multiple myeloma ((MM)). In addition, it is developing CB-012 for patients with relapsed/refractory acute myeloid leukemia ((AML)). The downside is that both of these candidates are in the very early stages of clinical development. They are each in IND-enabling and discovery stages respectively. Not only that, but it is developing iPSC-derived CAR-NK cell therapies. The reason why is that it has observed in early testing that it may be possible to counter the immunosuppressive tumor microenvironment with the use of CB-020. Additional results from the phase 1 ANTLER study, using CB-010 for the treatment of patients with relapsed/refractory B-cell Lymphoma are expected by the end of 2022. These are the reasons why I believe Caribou Bioscience is a great speculative biotech to look into. CB-010 For The Treatment Of Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma The main clinical program in the pipeline to go over involves the use of CB-010 for the treatment of patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. B-cell malignancies occur in B-cells (immune system cells) and most are non-Hodgkin Lymphomas. Lymphoma is cancer that develops in the lymphatic system, which is the body's fighting immune system network. The lymphatic system is composed of: Lymph Nodes, spleen, thymus gland and bone marrow area. This type of cancer affects these organs and several others. There are two main types of lymphomas that you are likely aware of, which are: Hodgkin's Lymphoma Non-Hodgkin's Lymphoma. These are the two main ones, although there are some other types. Both of these types are lymphomas that have problems with the B-cells in the body, which are responsible for fighting off infections in a person's body. The main difference is found under a microscope where each of the cells are shown to be different. There is a difference in the 5-year survival rates between Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma, which are shown directly below: Hodgkin's Lymphoma - More than 86% of patients diagnosed with this type of cancer survive 5 years or more Non-Hodgkin's Lymphoma - More than 70% of patients diagnosed with this type of cancer survive 5 years or more The main thing is that a majority of biotechs targeting the large non-Hodgkin's lymphoma market. That's because the global Non-Hodgkin's Lymphoma market is expected to reach $12.5 billion by 2027. This is a large market opportunity for any biotech. One important thing to note is that there is a specific focus for B-cells, which is the targeting of B-cells that express CD19. If you are thinking that the targeting of only CD19 expressed B-cells would limit market potential, then that would be a mistake. That's because B-cell malignancies express CD19 at normal to high levels as follows: 80% of acute lymphoblastic leukemia ((ALL)) 88% of B-cell lymphomas 100% of B-cell leukemia. As you can see, the targeting of CD19 specifically won't hinder the possible market opportunity. It dosed the first patient for the phase 1 ANTLER study back in July of 2021. This early-stage study intends to recruit about 50 patients and then evaluate them for safety and efficacy of CB-010 for the treatment of patients with relapsed/refractory B-cell Lymphoma. The primary endpoint for this trial is objective response rate ((ORR)). Thus far, I believe that this biotech is on the right track. Why do I state that? It is because it had seen excellent data from several patients that were only given one starting dose of CB-010 which is 40x106 CAR-T cells. It is important to note that this is dose level 1, because it is now in the process of dose level 2. Speaking of dose level 1 for this phase 1 ANTLER study, as I stated before, it was able to obtain impressive results just with one dose given at this level. It was revealed that there was a 100% complete response ((CR)) rate observed as best response as of the cutoff date of May 13, 2022. At 6 months following a single dose noted above, the CR was 40% (2 of 5 patients). This is not bad for patients only being given a single dose of therapy. Another item to note which I think is great is that 1 patient evaluated after the May 13, 2022, cutoff date maintained CR to 12 months. In addition, these were patients who had relapsed with prior treatments. They relapsed after a median of 3 prior therapies, ranging from 2 to 8 therapies. They were very sick patients to begin with. What comes next? Well, there is potential to improve efficacy. This can be done if dose level 2, which is 80x106 CAR-T cells, can achieve an improvement in terms of objective response rate over an extended period of time. A risk to be aware of is that dose level 1 consisted of adverse events which were consistent with other allogeneic and autologous CAR-Ts. This means that if adverse events are even worse with the next dose, there is a possibility that Caribou will have to stick with the current dose. I don't view this as a bad thing, being that one dose of CB-010 at dose level 1 is already strong as it is. Investors/traders wont' have to wait that long to see data from dose level 2. Additional results from the phase 1 ANTLER study are expected at the end of 2022. Improvement Of CAR-Ts Through PD-1 Knockout Why does this biotech hold the potential to change the landscape of CAR-T? The reason all has to do with the technology it has. That is, developing a CRISPR-edited allogeneic CAR-T, which can possibly improve persistence in the patient. More specifically, it is the first allogeneic CAR-T cell therapy to include edits to achieve this function. There are three edits which are done as follows: Inserting CD-19 specific CAR into the T-cell genome Remove TRAC gene in place to remove T-cell receptor Knockout gene encoding PD-1. The last bullet point above of knocking out PD-1 is especially important. It believes that knocking out PD-1 may lead to persistence of the CAR-T cell itself against the tumor. Other improvements with such an edit could be the ability to reduce CB-010 exhaustion. This makes a lot of sense, because while CAR-Ts are highly effective treatments, one major issue a lot of them lack is the ability to persist for an extended period of time. The first CAR-T CB-010 may possibly be advanced into the clinic quickly. Caribou believes that there is a chance for an eventual phase 2 study to be a registrational one. If the FDA sees compelling data in phase 1, then it's possible that it may allow a phase 2 study to become a registrational one. This all depends on unmet medical need, how good the data is and rules established by the agency at the time of a meeting. Additional CAR-Ts With Different Edits And Approaches As I noted above, CB-010 has 3 CRISPR edits in place to be altered. Well, what I think is interesting about Caribou is the ability to go a different route with its other allogenic CAR-Ts. What do I mean by that? Well, looking at the very next product in the pipeline CB-011, it incorporates 4 edits. The main edit to make note of is the ability to present a minor HLA class I antigen, which is responsible for removing T- and NK-mediated rejection of the CAR-T cell therapy by the patient's very own immune system. In essence, CB-011 incorporates what is known as immune cloaking to achieve this function. The other CAR-T in the pipeline known as CB-012 is being developed to target CLL-1 ((CD371)), which is expressed on Acute Myeloid Leukemia ((AML)) tumor cells and not on normal hematopoietic stem cells. There is a catalyst with respect to this clinical candidate. It is said that an IND application for the use of CB-011 for the treatment of patients with relapsed/refractory multiple myeloma ((MM)) is expected in the 2nd half of 2022.
|CRBU||US Biotechs||US Market|
Return vs Industry: CRBU underperformed the US Biotechs industry which returned -24.5% over the past year.
Return vs Market: CRBU underperformed the US Market which returned -12.8% over the past year.
|CRBU Average Weekly Movement||15.4%|
|Biotechs Industry Average Movement||12.9%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||17.1%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: CRBU is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: CRBU's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors.
Caribou Biosciences Fundamentals Summary
|CRBU fundamental statistics|
Is CRBU overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CRBU income statement (TTM)|
|Cost of Revenue||US$56.01m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.20|
|Net Profit Margin||-682.39%|
How did CRBU perform over the long term?See historical performance and comparison
Is CRBU undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CRBU?
Other financial metrics that can be useful for relative valuation.
|What is CRBU's n/a Ratio?|
Price to Sales Ratio vs Peers
How does CRBU's PS Ratio compare to its peers?
|CRBU PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
ALBO Albireo Pharma
RPTX Repare Therapeutics
CRBU Caribou Biosciences
Price-To-Sales vs Peers: CRBU is expensive based on its Price-To-Sales Ratio (48.6x) compared to the peer average (5.3x).
Price to Earnings Ratio vs Industry
How does CRBU's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: CRBU is expensive based on its Price-To-Sales Ratio (48.6x) compared to the US Biotechs industry average (16.7x)
Price to Sales Ratio vs Fair Ratio
What is CRBU's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||48.6x|
|Fair PS Ratio||0.06x|
Price-To-Sales vs Fair Ratio: CRBU is expensive based on its Price-To-Sales Ratio (48.6x) compared to the estimated Fair Price-To-Sales Ratio (0.1x).
Share Price vs Fair Value
What is the Fair Price of CRBU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CRBU's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CRBU's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Caribou Biosciences forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRBU is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CRBU is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CRBU is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CRBU's revenue (32.9% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: CRBU's revenue (32.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CRBU is forecast to be unprofitable in 3 years.
Discover growth companies
How has Caribou Biosciences performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: CRBU is currently unprofitable.
Growing Profit Margin: CRBU is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CRBU's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CRBU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRBU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (40.8%).
Return on Equity
High ROE: CRBU has a negative Return on Equity (-19.59%), as it is currently unprofitable.
Discover strong past performing companies
How is Caribou Biosciences's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CRBU's short term assets ($368.0M) exceed its short term liabilities ($26.7M).
Long Term Liabilities: CRBU's short term assets ($368.0M) exceed its long term liabilities ($47.5M).
Debt to Equity History and Analysis
Debt Level: CRBU is debt free.
Reducing Debt: CRBU had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CRBU has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: CRBU has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 35.9% each year.
Discover healthy companies
What is Caribou Biosciences's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CRBU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CRBU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CRBU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CRBU's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CRBU has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rachel Haurwitz (36 yo)
Dr. Rachel E. Haurwitz, Ph D., has been the President and Chief Executive Officer at Caribou Biosciences, Inc. since October 2011. She serves as an Independent Director at Seer, Inc since November 08, 2021...
CEO Compensation Analysis
Compensation vs Market: Rachel's total compensation ($USD6.25M) is above average for companies of similar size in the US market ($USD2.70M).
Compensation vs Earnings: Rachel's compensation has increased whilst the company is unprofitable.
Experienced Management: CRBU's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Experienced Board: CRBU's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7%.
Caribou Biosciences, Inc.'s employee growth, exchange listings and data sources
- Name: Caribou Biosciences, Inc.
- Ticker: CRBU
- Exchange: NasdaqGS
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$519.031m
- Shares outstanding: 60.71m
- Website: https://cariboubio.com
Number of Employees
- Caribou Biosciences, Inc.
- 2929 7th Street
- Suite 105
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/06 00:00|
|End of Day Share Price||2022/08/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.